China In Vivo Cro Market Size & Outlook, 2024-2030
Related Markets
China in vivo cro market highlights
- The China in vivo cro market generated a revenue of USD 102.7 million in 2023 and is expected to reach USD 188.6 million by 2030.
- The China market is expected to grow at a CAGR of 9.1% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
In vivo cro market data book summary
| Market revenue in 2023 | USD 102.7 million |
| Market revenue in 2030 | USD 188.6 million |
| Growth rate | 9.1% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, China accounted for 2.2% of the global in vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan in vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 122.7 million by 2030.
Small molecule was the largest segment with a revenue share of 63.58% in 2024. Horizon Databook has segmented the China in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
The growing demand for in vivo services in China can be underpinned by low operational costs, investments to improve technology, R&D capacity building, and adherence to global R&D standards & guidelines to meet international requirements.
Consequently, several players are outsourcing their preclinical services to Chinese firms, benefitting from the government’s effort to create a conducive environment for conducting preclinical studies that align with global standards and satisfy regulatory bodies.
This support from the government enhances the credibility and reliability of in vivo CRO services in China. Furthermore, operating in the drug discovery sector in China offers a significant advantage in terms of lower costs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China in vivo cro market size, by modality type, 2018-2030 (US$M)
China In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
